Ingredients maker Seppic has opened a laboratory dedicated to fermentation biotechnologies in the US.
The new facility, committed to developing new ingredients for the cosmetics and health fields, is located at parent company Air Liquide Group’s Innovation Campus Delaware.
Seppic's American Customer Technical Service Center has been based at the Delaware site since 2007.
France-headquartered Seppic said the technology would enable the production of biobased ingredients with limited impact on the environment and biodiversity.
The laboratory’s location is described as a significant step in Seppic’s internationalisation strategy for research and innovation.
The manufacturer anticipates it will benefit from strong synergies with Air Liquide Group’s R&D activities on the campus, as well as the dynamic American research ecosystem in the field of biotechnologies.
“Following the opening in 2024 of new research facilities at our Castres site in France, Seppic continues to invest in the future with this laboratory in the US,” said Seppic CEO Hannes Moeller.
“It will enable us to continue innovating for the performance of our ingredients by addressing the needs of our markets.”
Beauty industry names with an eye on biotech include Estée Lauder Companies, which announced a new BioTech Hub in Olen, Belgium, in December 2024.
And Shiseido, which selected a biotechnology start-up, Italy’s Bacfarm, as the winner of its annual innovation EMEA competition.
A bacteria-based UV protection ingredient from Bacfarm will be utilised by skin microbiome-focused beauty brand Gallinée, which Shiseido acquired in 2022.